Indegene Ltd Share Price & Stock Analysis

Indegene Ltd (NSE: INDGN, BSE: 544172) is a Bengaluru, Karnataka-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹14,840 Cr, it ranks #466 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 10 in Life Sciences Tools and Services. At ₹648.00 (as of 19 Nov 2026), the share price is 4.3% below its 52-week high of ₹677.00 and 56.5% above its 52-week low of ₹414.00. The share price is up 26.1% over one year and up 14.6% over three months.

Key Metrics

Current Price₹648.00
Market Cap₹14,840 Cr
NSE SymbolINDGN
BSE Code544172
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services
P/E Ratio40.2
Return on Equity13.94%
Return on Assets7.82%
52-Week Range₹414.00 – ₹677.00
1-Year Price Change+26.1%
3-Month Price Change+14.6%
Beta (1Y)0.38
Dividend Yield0.34%
HeadquartersBengaluru, Karnataka
Websitewww.indegene.com

Latest Quarterly Results — Q2 FY27

Revenue₹1,122 Cr
Net Profit₹112 Cr
Net Margin10.0%
EPS (Basic)₹4.67
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Indegene Ltd Quarterly Revenue and Profit Trend

Indegene Ltd reported revenue of ₹1,122 Cr in Q2 FY27, up 39.6% from ₹804 Cr in Q2 FY26 and up 5.6% from ₹1,063 Cr in Q1 FY27. It posted a net profit of ₹112 Cr for the quarter, against a net profit of ₹102 Cr in Q2 FY26 (up 10.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹756 Cr (Q4 FY25) to ₹1,122 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹1,122 Cr₹112 Cr10.0%
Q1 FY27₹1,063 Cr₹116 Cr10.9%
Q4 FY26₹1,003 Cr₹80 Cr7.9%
Q3 FY26₹942 Cr₹103 Cr10.9%
Q2 FY26₹804 Cr₹102 Cr12.7%
Q1 FY26₹761 Cr₹116 Cr15.3%
Q4 FY25₹756 Cr₹118 Cr15.6%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Indegene Ltd reports no promoter group in its shareholding filing for Sept 2026. Delivery averaged 60.2% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).

About Indegene Ltd

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.

Products and Services

1. Enterprise Medical Solutions-This segment offers enterprise medical solutions, including creation and review of medical content, medical communication review, pharmacovigilance, and other safety services, as well as labelling, regulatory submissions, and pricing and market access services. 2. Enterprise Commercial Solutions-This segment develops, deploys, and measures sales and marketing activities, including generation of marketing and promotional content. 3. Others-NA 4. Segment Adjustment-NA

Business Segments

1. Enterprise Medical Solutions-26.5% 2. Others-3.4% 3. Enterprise Commercial Solutions (Incl. Omnichannel Activation)-70.1%

Indegene Ltd vs Peers — Life Sciences Tools and Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Indegene Ltd₹14,840 Cr40.213.94%₹1,122 Cr+26.1%
Suven Life Sciences Ltd.₹7,951 Crn/m-78.80%₹1 Cr+51.8%
Vimta Labs Ltd₹2,259 Cr29.518.55%₹112 Cr-26.8%
Tarsons Products Limited₹1,730 Cr114.92.26%₹124 Cr+25.7%
Brooks Laboratories Ltd.₹198 Cr7.922.28%₹19 Cr-34.2%
Bilcare Ltd.₹194 Cr108.3-5.21%——
Jeevan Scientific Technology Ltd₹176 Cr129.41.68%—+42.3%
Vivo Bio Tech Ltd.₹37 Crn/m-2.00%₹14 Cr-55.7%
Dr. Habeebbullal Life Sciences Ltd₹26 Crn/m-68.79%—-45.3%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Indegene Ltd?

Indegene Ltd is trading at ₹648.00, with a market capitalisation of ₹14,840 Cr.

Which sector does Indegene Ltd belong to?

Indegene Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).

What are the key financial ratios of Indegene Ltd?

Indegene Ltd has a P/E of 40.2 and a return on equity of 13.94%.

What is the stock symbol of Indegene Ltd?

Indegene Ltd is listed on the NSE under the symbol INDGN and on the BSE under the scrip code 544172.

How has Indegene Ltd's share price moved over the past year?

Indegene Ltd's share price is up 26.1% over one year and up 14.6% over three months. Its 52-week range is ₹414.00 to ₹677.00.

What were Indegene Ltd's latest quarterly results?

In Q2 FY27, Indegene Ltd reported revenue of ₹1,122 Cr and net profit of ₹112 Cr, with basic EPS of ₹4.67 (consolidated, parsed from the company's exchange filing).

How have Indegene Ltd's revenue and profit changed over the past year?

Indegene Ltd reported revenue of ₹1,122 Cr in Q2 FY27, up 39.6% from ₹804 Cr in Q2 FY26 and up 5.6% from ₹1,063 Cr in Q1 FY27.

What is the promoter holding in Indegene Ltd?

Indegene Ltd reports no promoter group in its shareholding filing for Sept 2026.

More on FinBizNet

Data as of 19 Nov 2026. Descriptive market data only — not investment advice.